Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Efgartigimod IV in Renal Impairment
NCT05927415Phase 1Completed
- Sponsor
- argenx
- Start
- Jul 2023
- Primary completion
- Jun 2024
- Modality
- Antibody Fragments
- Countries
- 1
01
Overview
Phase 1, open-label trial of efgartigimod alfa in myasthenia gravis (MG) (4 arms), sponsored by argenx. Primary endpoint: Maximum observed plasma concentration up to 64 days. Started Jul 2023; status: completed.
02
Drugs
efgartigimod alfa
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT05927415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05927415.